- Letter to the Editor
- Open Access
The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19
Respiratory Research volume 21, Article number: 178 (2020)
Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.
Letter to the editor
Neonatal Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). By the end of March 2020, during the unpreceded global health crisis generated by the COVID-19 pandemic, a few ecological studies suggested a protective effect of the BCG vaccine, with less morbidity and lower mortality from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [1,2,3,4]. These studies have drawn attention to this century-old vaccine and a few clinical trials are underway to repurpose BCG vaccination.
According to these studies, the incidence of COVID-19 is four times higher, with a 21-fold increase in death rates in high- and middle-income countries (HMIC) without universal BCG vaccination when compared to those with this policy . The earlier the implementation of the policy in the country, the lower the number of COVID-19 related deaths, possibly due to a larger proportion of vaccinated older adults [1, 2]. However, those studies included countries that were still in early phases of the epidemic back then, including Brazil, which now accounts with the highest number of daily COVID-19 deaths. Also, the observed association was not sustained in countries with high COVID-19 testing rates [3, 4].
The potential protective effect of neonatal BCG vaccination on COVID-19 severity was suggested due to the lower COVID-19 mortality in some European and Asian countries (China, South Corea, India, Russia and Japan), where the vaccination is mandatory [5, 6]. Additionally, COVID-19 mortality is higher where BCG vaccination has been discontinued for more than 20 years . France, for instance, registered lower COVID-19 mortality than Italy, where the vaccination is no longer mandatory [5,6,7,8]. However, there is conflicting data on the protective effect of BCG vaccination. In Italy, BCG vaccination was interrupted in 2001 and COVID-19 mortality rates were high among elders [5,6,7,8]. In the UK, where BCG vaccination was recently restarted for TB high-risk groups such as migrants and individuals living in social deprived conditions, COVID-19 mortality rates were higher in these groups than in the overall population [5–8]. Finally, countries using the original BCG strains registered lower COVID-19 case fatality rate if compared to European countries that are using modified BCG strains (Japan - 5.4%; Brazil- 4.7% and Rússia-1.4% vs France-15.1%, Italy- 14.5% and United Kingdom 14.0%) [5,6,7,8], suggesting that different BCG strains can have different effects on COVID-19 severity and mortality. Regardless of the controversial findings, ecological bias and the large numbers of potential confounders, such as age, socio-economic factors, health system capacity, stage of the epidemic and the proportion of the population tested, among others, hamper the confiability of these ecological observations and the inference to the individual level.
The alleged protective effect could be the result of trained immunity stimulation from BCG. BCG vaccination can reduce viremia from other respiratory tract viral infections [9, 10]. This would be achieved by boosting non-specific Th1 and Th17 responses for at least one year after vaccination , inducing trained immunity, the equivalent of immunological memory for the innate immune response. BCG vaccination followed by a challenge with attenuated Yellow Fever Virus leads to macrophage reprogramming, with a central role of interleukin 1 beta (Il-1b), a hallmark of trained immunity . Trained immunity results in a long-lasting functional programming of innate immune cells that, even in a quiescent state, can be recovered by endogenous or exogenous stimuli resulting in a better-regulated response against a new challenge .
In the absence of a specific treatment and vaccine for COVID-19, even a small protective effect of a cheap and safe vaccine such as BCG could be a valuable tool for fighting the disease. If this effect can be confirmed by higher-quality evidence, BCG vaccine could be used to improve clinical outcomes of the most vulnerable, reducing the need for hospital beds, ventilators, and the overall impact on LMIC countries’ fragile health systems. Additionally, applied to healthcare professionals, it could protect the healthcare force, reducing the burden upon them, and the absenteeism from the disease.
High-income countries without BCG vaccination recommendations are planning clinical trials to test the protective effect of BCG on COVID-19 among healthcare workers and older adults [12, 13]. To support the rationale of these trials, LMIC such as Brazil, where BCG vaccination has been used since 1929 - with universal coverage since 1973, are strategic to provide timely evidence on this potential effect of the BCG vaccine, by conducting large case-control studies, which are usually faster and less expensive than clinical trials. Our group is currently using Brazilian routine programmatic data from the existing information systems to analyse the effect of neonatal BCG immunization on COVID-19 clinical outcomes. In addition, data from a large randomized clinical trial (REVAC-BCG), conducted in over 350 thousand school-aged children in two large Brazilian cities in 1996–1997 to investigate the effect of BCG vaccination and revaccination on tuberculosis is being linked to the COVID-19 database to provide more insights on this matter . As the BCG revaccination was ineffective for protection against tuberculosis, the control arm was not revaccinated; thus, the randomization carried out in the past is still valid over the years.
Producing high-quality evidence of the effect of BCG vaccination on COVID-19 outcomes is essential for decision-makers to eventually recommend the BCG vaccination as a possible intervention for COVID-19. We urge colleagues from LMIC where BCG vaccination policies are in course to produce fast, trustable, and low-cost evidence about the effect of the BCG vaccine on the COVID-19 pandemic, while trials are underway. In case the results are positive, it would summ up with the results of the trials in HMIC in course to speed the decisions on the best rationale for using BCG in the current and future possible waves of the pandemics.
Availability of data and materials
High- and middle-income countries
Interleukin 1 beta
Low- and middle-income countries
Severe acute respiratory syndrome coronavirus 2
Brazilian rendomized trial on revaccination of pre-high school children for protection againt tuberculosis
Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv. 2020. https://doi.org/10.1101/2020.03.24.20042937.
Shet A, Ray D, Malavige N, Santosham M, Bar-Zeev N. Differential COVID-19-attributable mortality and BCG vaccine use in countries. medRxiv. 2020. https://doi.org/10.1101/2020.04.01.20049478.
Szigeti R, Kellermayer D, Kellermayer R. BCG protects against COVID-19? A word of caution. medRxiv. 2020:2020.04.09.20056903. https://doi.org/10.1101/2020.04.09.20056903.
Hensel J, McGrail DJ, McAndrews KM, Dowlatshahi D, LeBleu VS, Kalluri R. Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing. medRxiv. 2020. https://doi.org/10.1101/2020.04.08.20056051.
Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012. https://doi.org/10.1371/journal.pmed.1001012.
Johns Hopkins University. Coronavirus Resource Center: Mortality Analyses. Available in: https://coronavirus.jhu.edu/data/mortality. Accessed 20 June 2020.
Iwasaki A, Grubaugh ND. Why does Japan have so few cases of COVID-19? EMBO Mol Med. 2020;12(5):e12481. https://doi.org/10.15252/emmm.202012481.
Miyasaka M. Is BCG vaccination causally related to reduced COVID-19 mortality? EMBO Mol Med. 2020;12(6):e12661. https://doi.org/10.15252/emmm.202012661.
Arts RJW, Moorlag SJCFM, Novakovic B, et al. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe. 2018;23(1):89–100.e5. https://doi.org/10.1016/j.chom.2017.12.010.
Hollm-Delgado M-G, Stuart EA, Black RE. Acute lower respiratory infection among Bacille Calmette-Guerin (BCG)-vaccinated children. Pediatrics. 2014;133(1):e73–81. https://doi.org/10.1542/peds.2013-2218.
Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020 Mar 4. https://doi.org/10.1038/s41577-020-0285-6 [Epub ahead of print].
Ziekenhuis JB, Ziekenhuis CW, Radboud UMC, et al. Reducing health care workers absenteeism in Covid-19 pandemic through BCG vaccine (BCG-CORONA). Clinical trial: NCT04328441. Available in: https://clinicaltrials.gov/ct2/show/NCT04328441?term=BCG&cond=COVID&draw=2&rank=1. Accessed 19 Apr 2020.
Curtis N, Gardiner K. BCG vaccination to protect healthcare workers against COVID-19 (BRACE). Clinical trial: NCT04327206. Available in: https://clinicaltrials.gov/ct2/show/NCT04327206?term=BCG&cond=COVID&draw=2&rank=4. Accessed 19 Apr 2020.
Rodrigues LC, Pereira SM, Cunha SS, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet. 2005;366(9493):1290–5. https://doi.org/10.1016/S0140-6736(05)67145-0.
Ethics approval and consent to participate
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Pereira, M., Paixão, E., Trajman, A. et al. The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19. Respir Res 21, 178 (2020). https://doi.org/10.1186/s12931-020-01439-4